Breakthroughs in dendritic cell-cytokine-induced killer therapy for non-small cell lung cancer

With the increasing adoption of immunotherapy in oncology, dendritic cell-cytokine-induced killer (DC-CIK) autologous cell immunotherapy has emerged as a promising strategy for the treatment of non-small cell lung cancer (NSCLC). This approach leverages the patient’s immune system by stimulating the proliferation and activation of T lymphocytes, thereby enhancing the anti-tumor immune responses. Clinical trials have demonstrated notable improvements in both immunological outcomes and clinical efficacy, with DC-CIK therapy contributing to prolonged survival and improved quality of life for NSCLC, while maintaining an acceptable safety profile. Despite these advancements, challenges remain, necessitating further comprehensive clinical studies to establish the long-term efficacy and survival benefits of DC-CIK therapy.